Alphamab Oncology (HKG:9966)
Hong Kong · Delayed Price · Currency is HKD 7.70
-0.04 (-0.52%)
At close: Mar 27, 2026
Alphamab Oncology Market Cap
Alphamab Oncology has a market cap or net worth of 7.46 billion as of March 27, 2026. Its market cap has increased by 28.09% in one year.
Market Cap
7.46B
Enterprise Value
6.09B
Revenue
630.11M
Ranking
n/a
PE Ratio
n/a
Stock Price
7.70
Market Cap Chart
Since December 12, 2019, Alphamab Oncology's market cap has decreased from 12.11B to 7.46B, a decrease of -38.41%. That is a compound annual growth rate of -7.42%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 26, 2026 | 7.50B | -21.02% |
| Dec 31, 2025 | 9.49B | 181.80% |
| Dec 31, 2024 | 3.37B | -47.42% |
| Dec 29, 2023 | 6.41B | -36.87% |
| Dec 30, 2022 | 10.15B | -20.36% |
| Dec 31, 2021 | 12.74B | -16.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 12, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Lepu Biopharma | 10.10B |
| HBM Holdings | 9.95B |
| CARsgen Therapeutics Holdings | 9.70B |
| Guangzhou Innogen Pharmaceutical Group | 9.55B |
| Shanghai Haohai Biological Technology | 9.06B |
| Abbisko Cayman | 8.37B |
| CK Life Sciences Int'l., (Holdings) | 6.44B |
| Laekna | 6.42B |